Bradley Saenger

CIK: 0001668150

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNXP

Tonix Pharmaceuticals Holding Corp.

Officer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (7 total)

TNXP
Tonix Pharmaceuticals Holding Corp.
Jun 30, 2026
Other(J)
Direct
1.5K shares at avg. $10.91$16K
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
39K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
39K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Dec 31, 2025
Award(A)
Direct
701 shares at avg. $13.42$9K
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
25.8K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
25.8K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Direct
0 shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	1,453	$10.91	$15,858	Direct
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	39,012	-	-	Direct
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	39,011	-	-	Direct
Dec 31, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A)	701	$13.42	$9,407	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	25,792	-	-	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	25,792	-	-	Direct
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	0	-	-	Direct

1-7 of 7 transactions

About SAENGER BRADLEY

SAENGER BRADLEY (SEC CIK 0001668150) files insider reports with the SEC as Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 4 ownership filings by SAENGER BRADLEY (3 Form 4, 1 Form 5), filed between Feb 27, 2025 and Jul 9, 2026. Those filings report 7 transactions, from Feb 5, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SAENGER BRADLEY's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by SAENGER BRADLEY

Jun 30, 2026: Other transaction of TNXP shares (Form 4, code J).
Feb 24, 2026: Grants or awards of TNXP derivative securities (2 lines, Form 4, code A).
Dec 31, 2025: Grant or award of TNXP shares (Form 5, code A).
Feb 25, 2025: Grants or awards of TNXP derivative securities (2 lines, Form 4, code A).
Feb 5, 2025: Other transaction of TNXP shares (Form 4, code J).

Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)

Englese Thomas, Chief Commercial Officer
BAGGER RICHARD H, Director
Taylor Carolyn E., Director
Stillwell Richard Newcomb, Director
LEDERMAN SETH, Chief Executive Officer
OLUKOTUN ADEOYE Y, Director

How to read Form 4 transaction codes